Abbvie Gross Profit

The latest gross profit for ABBV is $53B as of June 2026. That compares with $23B in the prior-year period — up 133.1% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Abbvie's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABBV's gross profit moved from $23B to $53B — a 133.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Abbvie's operating scale or balance-sheet position.

Against Healthcare companies, ABBV currently prints $53B for gross profit, while the sector average sits near $66B. That is roughly 18.8% below the sector mean. Large gaps often invite a closer look at Abbvie's growth, margins, and balance sheet.

A gross profit figure of $53B for ABBV is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting ABBV's gross profit ($53B), review year-over-year change from $23B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.